EIKN (Eikon Therapeutics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by EIKN officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-08 | Column Group IV-A, LP | 10%+ Owner | Buy | — | — |
| 2026-03-04 | Michael A Klobuchar | Chief Operating Officer | A | — | — |
| 2026-03-04 | Robert Luther Huffines | Director | A | — | — |
| 2026-03-04 | Alfred Lloyd Bowie Jr. | Chief Financial Officer | A | — | — |
| 2026-03-04 | Roy D. Baynes | Chief Medical Officer | A | — | — |
| 2026-03-04 | KENNETH C FRAZIER | Director | A | — | — |
| 2026-03-04 | ROGER M PERLMUTTER | See remarks | A | — | — |
| 2026-03-04 | Benjamin Bruno Thorner | See Remarks | A | — | — |
| 2026-02-10 | ROGER M PERLMUTTER | See remarks | C | — | — |
| 2026-02-09 | TCG Opportunity III GP, LLC | 10%+ Owner | MIXED | — | — |
| 2026-02-06 | KENNETH C FRAZIER | Director | Buy | — | — |
| 2026-02-06 | Josh Wolfe | Director | MIXED | — | — |
| 2026-02-06 | Lux Ventures V, L.P. | 10%+ Owner | MIXED | — | — |
| 2026-02-06 | Foresite Capital VI-A, LLC | 10%+ Owner | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 4,312,139 | — |
| — | 10%+ Owner | 2,294,653 | — |
| — | 10%+ Owner | 386,797 | — |
| — | See remarks | 284,857 | — |
| — | 10%+ Owner | 148,840 | — |
| — | Director | 138,888 | — |
| — | Director | 111,111 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the EIKN quote page; the site-wide leaderboard is on the insider transactions hub.